DOCSLIB.ORG

Acid Dissociation Constants

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acid Dissociation Constants 29 November 2009 at 13:29 Name Synonym Mol. Form. CAS Reg. No. Mol. Wt. Step t/°C pKa Acetaldehyde Ethanal C2H4O 75-07-0 44.052 25 13.57 Acetamide Ethanamide C2H5NO 60-35-5 59.067 25 15.1 Acetanilide N-Phenylacetamide C8H9NO 103-84-4 135.163 25 0.5 Acetazolamide N-[5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide C4H6N4O3S2 59-66-5 222.246 7.2 Acetic acid Ethanoic acid C2H4O2 64-19-7 60.052 25 4.756 Acetoacetic acid C4H6O3 541-50-4 102.089 25 3.6 Acetohydroxamic acid N-Hydroxyacetamide C2H5NO2 546-88-3 75.067 8.70 N-Acetylglycine Aceturic acid C4H7NO3 543-24-8 117.104 25 3.67 2-(Acetyloxy)benzoic acid Acetylsalicylic acid C9H8O4 50-78-2 180.158 25 3.48 Aconine C25H41NO9 509-20-6 499.596 9.52 Aconitine C34H47NO11 302-27-2 645.737 5.88 9-Acridinamine Aminacrine C13H10N2 90-45-9 194.231 20 9.99 Acridine Dibenzo[b,e]pyridine C13H9N 260-94-6 179.217 20 5.58 3,6-Acridinediamine Proflavine C13H11N3 92-62-6 209.246 20 9.65 Acrylic acid 2-Propenoic acid C3H4O2 79-10-7 72.063 25 4.25 Adenine 1H-Purin-6-amine C5H5N5 73-24-5 135.128 1 4.3 Adenine 1H-Purin-6-amine C5H5N5 73-24-5 135.128 2 9.83 Adenosine β-D-Ribofuranoside, adenine-9 C10H13N5O4 58-61-7 267.242 1 25 3.6 Adenosine β-D-Ribofuranoside, adenine-9 C10H13N5O4 58-61-7 267.242 2 25 12.4 5'-Adenylic acid Adenosine 5'-monophosphate C10H14N5O7P 61-19-8 347.222 1 3.8 5'-Adenylic acid Adenosine 5'-monophosphate C10H14N5O7P 61-19-8 347.222 2 6.2 Adipamic acid C6H11NO3 334-25-8 145.156 25 4.63 Agaritine L-Glutamic acid, 5-[2-[4-(hydroxymethyl)phenyl]hydrazide] C12H17N3O4 2757-90-6 267.281 1 3.4 Agaritine L-Glutamic acid, 5-[2-[4-(hydroxymethyl)phenyl]hydrazide] C12H17N3O4 2757-90-6 267.281 2 8.86 L-Alanine 2-Aminopropanoic acid, (S)- C3H7NO2 56-41-7 89.094 1 25 2.34 L-Alanine 2-Aminopropanoic acid, (S)- C3H7NO2 56-41-7 89.094 2 25 9.87 β-Alanine 3-Aminopropanoic acid C3H7NO2 107-95-9 89.094 1 25 3.55 β-Alanine 3-Aminopropanoic acid C3H7NO2 107-95-9 89.094 2 25 10.24 Allantoin C4H6N4O3 97-59-6 158.116 25 8.96 Allopurinol 1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one C5H4N4O 315-30-0 136.112 10.2 Alloxanic acid C4H4N2O5 470-44-0 160.085 25 6.64 Allyl alcohol 2-Propen-1-ol C3H6O 107-18-6 58.079 25 15.5 Allylamine 2-Propen-1-amine C3H7N 107-11-9 57.095 25 9.49 N-Allylaniline Allylphenylamine C9H11N 589-09-3 133.190 25 4.17 Aminoacetonitrile C2H4N2 540-61-4 56.066 25 5.34 2-Aminoadipic acid C6H11NO4 626-71-1 161.156 1 25 2.14 2-Aminoadipic acid C6H11NO4 626-71-1 161.156 2 25 4.21 2-Aminoadipic acid C6H11NO4 626-71-1 161.156 3 25 9.77 4-Aminoazobenzene C12H11N3 60-09-3 197.235 25 2.82 2-Aminobenzenesulfonic acid Orthanilic acid C6H7NO3S 88-21-1 173.190 25 2.46 3-Aminobenzenesulfonic acid Metanilic acid C6H7NO3S 121-47-1 173.190 25 3.74 4-Aminobenzenesulfonic acid Sulfanilic acid C6H7NO3S 121-57-3 173.190 25 3.23 2-Aminobenzonitrile C7H6N2 1885-29-6 118.136 25 0.77 3-Aminobenzonitrile C7H6N2 2237-30-1 118.136 25 2.75 4-Aminobenzonitrile C7H6N2 873-74-5 118.136 25 1.74 2-Aminobiphenyl C12H11N 90-41-5 169.222 25 3.83 3-Aminobiphenyl C12H11N 2243-47-2 169.222 18 4.25 4-Aminobiphenyl p-Biphenylamine C12H11N 92-67-1 169.222 18 4.35 DL-2-Aminobutanoic acid C4H9NO2 2835-81-6 103.120 1 25 2.29 DL-2-Aminobutanoic acid C4H9NO2 2835-81-6 103.120 2 25 9.83 4-Aminobutanoic acid γ-Aminobutyric acid C4H9NO2 56-12-2 103.120 1 25 4.031 4-Aminobutanoic acid γ-Aminobutyric acid C4H9NO2 56-12-2 103.120 2 25 10.556 2-Aminoethanesulfonic acid Taurine C2H7NO3S 107-35-7 125.147 1 25 1.5 2-Aminoethanesulfonic acid Taurine C2H7NO3S 107-35-7 125.147 2 25 9.06 4-(2-Aminoethyl)phenol Tyramine C8H11NO 51-67-2 137.179 1 25 9.74 4-(2-Aminoethyl)phenol Tyramine C8H11NO 51-67-2 137.179 2 25 10.52 6-Aminohexanoic acid ε-Aminocaproic acid C6H13NO2 60-32-2 131.173 1 25 4.37 6-Aminohexanoic acid ε-Aminocaproic acid C6H13NO2 60-32-2 131.173 2 25 10.80 Copyright © CRC Press 2004 Page 1 29 November 2009 at 13:29 4-Amino-2-hydroxybenzoic acid p-Aminosalicylic acid C7H7NO3 65-49-6 153.136 3.25 2-Amino-4-hydroxypteridine C6H5N5O 2236-60-4 163.137 1 20 2.27 2-Amino-4-hydroxypteridine C6H5N5O 2236-60-4 163.137 2 20 7.96 5-Amino-1-naphthol 1-Amino-6-hydroxynaphthalene C10H9NO 83-55-6 159.184 25 3.97 5-Amino-4-oxopentanoic acid 5-Aminolevulinic acid C5H9NO3 106-60-5 131.130 1 25 4.05 5-Amino-4-oxopentanoic acid 5-Aminolevulinic acid C5H9NO3 106-60-5 131.130 2 25 8.90 5-Aminopentanoic acid C5H11NO2 660-88-8 117.147 1 25 4.27 5-Aminopentanoic acid C5H11NO2 660-88-8 117.147 2 25 10.77 2-Aminophenol C6H7NO 95-55-6 109.126 1 20 4.78 2-Aminophenol C6H7NO 95-55-6 109.126 2 20 9.97 3-Aminophenol C6H7NO 591-27-5 109.126 1 20 4.37 3-Aminophenol C6H7NO 591-27-5 109.126 2 20 9.82 4-Aminophenol C6H7NO 123-30-8 109.126 1 25 5.48 4-Aminophenol C6H7NO 123-30-8 109.126 2 25 10.30 3-Aminopropanenitrile 3-Aminopropionitrile C3H6N2 151-18-8 70.093 20 7.80 4-Amino-3,5,6-trichloro-2-pyridinecarboxlic acid Picloram C6H3Cl3N2O2 1918-02-1 241.459 3.6 Amiodarone C25H29I2NO3 1951-25-3 645.312 25 6.56 Amitriptyline C20H23N 50-48-6 277.404 9.4 Amobarbital 5-Ethyl-5-isopentyl-2,4,6(1H,3H,5H)-pyrimidinetrione C11H18N2O3 57-43-2 226.272 25 8.0 Aniline Benzenamine C6H7N 62-53-3 93.127 25 4.87 Aniline-2-carboxylic acid o-Anthranilic acid C7H7NO2 118-92-3 137.137 1 25 2.17 Aniline-2-carboxylic acid o-Anthranilic acid C7H7NO2 118-92-3 137.137 2 25 4.85 Aniline-3-carboxylic acid m-Anthranilic acid C7H7NO2 99-05-8 137.137 1 25 3.07 Aniline-3-carboxylic acid m-Anthranilic acid C7H7NO2 99-05-8 137.137 2 25 4.79 Aniline-4-carboxylic acid p-Anthranilic acid C7H7NO2 150-13-0 137.137 1 25 2.50 Aniline-4-carboxylic acid p-Anthranilic acid C7H7NO2 150-13-0 137.137 2 25 4.87 Apomorphine C17H17NO2 58-00-4 267.323 1 7.0 Apomorphine C17H17NO2 58-00-4 267.323 2 8.92 Arecoline C8H13NO2 63-75-2 155.195 6.84 L-Arginine C6H14N4O2 74-79-3 174.201 1 25 1.82 L-Arginine C6H14N4O2 74-79-3 174.201 2 25 8.99 L-Arginine C6H14N4O2 74-79-3 174.201 3 25 12.5 L-Argininosuccinic acid C10H18N4O5 2387-71-5 274.274 1 25 1.62 L-Argininosuccinic acid C10H18N4O5 2387-71-5 274.274 2 25 2.70 L-Argininosuccinic acid C10H18N4O5 2387-71-5 274.274 3 25 4.26 L-Argininosuccinic acid C10H18N4O5 2387-71-5 274.274 4 25 9.58 L-Ascorbic acid Vitamin C C6H8O6 50-81-7 176.124 1 25 4.04 L-Ascorbic acid Vitamin C C6H8O6 50-81-7 176.124 2 16 11.7 L-Asparagine α-Aminosuccinamic acid C4H8N2O3 70-47-3 132.118 1 20 2.1 L-Asparagine α-Aminosuccinamic acid C4H8N2O3 70-47-3 132.118 2 20 8.80 L-Aspartic acid L-Aminosuccinic acid C4H7NO4 56-84-8 133.104 1 25 1.99 L-Aspartic acid L-Aminosuccinic acid C4H7NO4 56-84-8 133.104 2 25 3.90 L-Aspartic acid L-Aminosuccinic acid C4H7NO4 56-84-8 133.104 3 25 9.90 Aspergillic acid C12H20N2O2 490-02-8 224.299 5.5 Atenolol C14H22N2O3 29122-68-7 266.336 9.6 Atisine Anthorine C22H33NO2 466-43-3 343.503 12.2 Azaserine C5H7N3O4 115-02-6 173.128 8.55 Azathioprine 1H-Purine, 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]- C9H7N7O2S 446-86-6 277.263 8.2 6-Azauridine 2-β-D-Ribofuranosyl-1,2,4-triazine-3,5(2H,4H)-dione C8H11N3O6 54-25-1 245.189 6.70 Azetidine C3H7N 503-29-7 57.095 25 11.29 Barbital 5,5-Diethylbarbituric acid C8H12N2O3 57-44-3 184.192 25 7.43 Barbituric acid C4H4N2O3 67-52-7 128.086 25 4.01 Benzaldehyde Benzenecarboxaldehyde C7H6O 100-52-7 106.122 25 14.90 Benzamide Benzoic acid amide C7H7NO 55-21-0 121.137 25 ≈13 Benzeneacetic acid Phenylacetic acid C8H8O2 103-82-2 136.149 25 4.31 Benzeneboronic acid C6H7BO2 98-80-6 121.930 8.83 Benzenebutanoic acid C10H12O2 1821-12-1 164.201 25 4.76 1,2-Benzenediamine o-Phenylenediamine C6H8N2 95-54-5 108.141 1 20 4.57 1,2-Benzenediamine o-Phenylenediamine C6H8N2 95-54-5 108.141 2 20 0.80 Copyright © CRC Press 2004 Page 2 29 November 2009 at 13:29 1,3-Benzenediamine m-Phenylenediamine C6H8N2 108-45-2 108.141 1 20 5.11 1,3-Benzenediamine m-Phenylenediamine C6H8N2 108-45-2 108.141 2 20 2.50 1,4-Benzenediamine p-Phenylenediamine C6H8N2 106-50-3 108.141 1 20 6.31 1,4-Benzenediamine p-Phenylenediamine C6H8N2 106-50-3 108.141 2 20 2.97 Benzeneethanamine 2-Phenylethylamine C8H11N 64-04-0 121.180 25 9.83 Benzenemethanethiol Thiobenzyl alcohol C7H8S 100-53-8 124.204 25 9.43 Benzenepropanoic acid Hydrocinnamic acid C9H10O2 501-52-0 150.174 25 4.66 Benzenesulfinic acid C6H6O2S 618-41-7 142.176 20 1.3 Benzenesulfonic acid Besylic acid C6H6O3S 98-11-3 158.175 25 0.70 Benzenethiol Phenyl mercaptan C6H6S 108-98-5 110.177 25 6.62 p-Benzidine [1,1'-Biphenyl]-4,4'-diamine C12H12N2 92-87-5 184.236 1 20 4.65 p-Benzidine [1,1'-Biphenyl]-4,4'-diamine C12H12N2 92-87-5 184.236 2 20 3.43 1H-Benzimidazole N,N'-Methenyl-o-phenylenediamine C7H6N2 51-17-2 118.136 25 5.53 Benzoic acid Benzenecarboxylic acid C7H6O2 65-85-0 122.122 25 4.204 1H-Benzotriazole 1,2,3-Triaza-1H-indene C6H5N3 95-14-7 119.124 20 1.6 N-Benzoylglycine Hippuric acid C9H9NO3 495-69-2 179.172 25 3.62 Benzpiperylon 1,2-Dihydro-2-(1-methyl-4-piperidinyl)-5-phenyl-4-benzyl- C22H25N3O 53-89-4 347.453 1 6.73 3H-pyrazol-3-one Benzpiperylon 1,2-Dihydro-2-(1-methyl-4-piperidinyl)-5-phenyl-4-benzyl- C22H25N3O 53-89-4 347.453 2 9.13 3H-pyrazol-3-one Benzylamine Benzenemethanamine C7H9N 100-46-9 107.153 25 9.34 4-Benzylaniline C13H13N 1135-12-2 183.249 25 2.17 2-Benzylpyridine C12H11N 101-82-6 169.222 25 5.13 Betaine 1-Carboxy-N,N,N-trimethylmethanaminium, inner salt C5H11NO2 107-43-7 117.147 0 1.83 Biguanide Imidodicarbonimidic diamide C2H7N5 56-03-1 101.111 1 11.52 Biguanide Imidodicarbonimidic diamide C2H7N5 56-03-1 101.111 2 2.93 N,N-Bis(2-hydroxyethyl)glycine Bicine C6H13NO4 150-25-4 163.172 2 20 8.35 Bithionol C12H6Cl4O2S 97-18-7 356.052 1 4.82 Bithionol C12H6Cl4O2S 97-18-7 356.052 2 10.50 Bornylamine 1,7,7-Trimethylbicyclo[2.2.1]heptan-2-amine,
Load more

Recommended publications
  • Cloning, Biochemical Characterization and Inhibition of Alanine Racemase from Streptococcus Iniae
    bioRxiv preprint doi: https://doi.org/10.1101/611251; this version posted April 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Cloning, Biochemical Characterization and Inhibition of Alanine racemase from Streptococcus iniae Murtala Muhammad, Yangyang Li, Siyu Gong, Yanmin Shi, Jiansong Ju, Baohua Zhao*, Dong Liu* College of Life Science, Hebei Normal University, Shijiazhuang 050024, China; *Correspondence: Baohua Zhao and Dong Liu; E-mail: [email protected], [email protected]; College of Life Science, Hebei Normal University, Shijiazhuang 050024, China. Running Title: Inhibitors of alanine racemase Summary statement: Antimicrobial target 1 bioRxiv preprint doi: https://doi.org/10.1101/611251; this version posted April 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Streptococcus iniae is a pathogenic and zoonotic bacteria that impacted high mortality to many fish species, as well as capable of causing serious disease to humans. Alanine racemase (Alr, EC 5.1.1.1) is a pyridoxal-5′-phosphate (PLP)-containing homodimeric enzyme that catalyzes the racemization of L-alanine and D-alanine. In this study, we purified alanine racemase from the pathogenic strain of S. iniae, determined its biochemical characteristics and inhibitors. The alr gene has an open reading frame (ORF) of 1107 bp, encoding a protein of 369 amino acids, which has a molecular mass of 40 kDa. The optimal enzyme activity occurred at 35°C and a pH of 9.5.
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Review Article
    REVIEW ARTICLE COLLAGEN METABOLISM COLLAGEN METABOLISM Types of Collagen 228 Structure of Collagen Molecules 230 Synthesis and Processing of Procollagen Polypeptides 232 Transcription and Translation 233 Posttranslational Modifications 233 Extracellular Processing of Procollagen and Collagen Fibrillogenesis 240 Functions of Collagen in Connective rissue 243 Collagen Degradation 245 Regulation of the Metabolism of Collagen 246 Heritable Diseases of Collagen 247 Recessive Dermatosparaxis 248 Recessive Forms of EDS 251 EDS VI 251 EDS VII 252 EDS V 252 Lysyl Oxidase Deficiency in the Mouse 253 X-Linked Cutis Laxa 253 Menke's Kinky Hair Syndrome 253 Homocystinuria 254 EDS IV 254 Dominant Forms of EDS 254 Dominant Collagen Packing Defect I 255 Dominant and Recessive Forms of Osteogenesis Imperfecta 258 Dominant and Recessive Forms of Cutis Laxa 258 The Marfan Syndrome 259 Acquired Diseases and Repair Processes Affecting Collagen 259 Acquired Changes in the Types of Collagen Synthesis 260 Acquired Changes in Amounts of Collagen Synthesized 263 Acquired Changes in Hydroxylation of Proline and Lysine 264 Acquired Changes in Collagen Cross-Links 265 Acquired Defects in Collagen Degradation 267 Conclusion 267 Bibliography 267 Collagen Metabolism A Comparison of Diseases of Collagen and Diseases Affecting Collagen Ronald R. Minor, VMD, PhD COLLAGEN CONSTITUTES approximately one third of the body's total protein, and changes in synthesis and/or degradation of colla- gen occur in nearly every disease process. There are also a number of newly described specific diseases of collagen in both man and domestic animals. Thus, an understanding of the synthesis, deposition, and turnover of collagen is important for the pathologist, the clinician, and the basic scientist alike.
    [Show full text]
  • A Study of the Decomposition of Some Aromatic Diazonium Hexafluorophosphate Salts
    University of Windsor Scholarship at UWindsor Electronic Theses and Dissertations Theses, Dissertations, and Major Papers 1-1-1964 A study of the decomposition of some aromatic diazonium hexafluorophosphate salts. William A. Redmond University of Windsor Follow this and additional works at: https://scholar.uwindsor.ca/etd Recommended Citation Redmond, William A., "A study of the decomposition of some aromatic diazonium hexafluorophosphate salts." (1964). Electronic Theses and Dissertations. 6038. https://scholar.uwindsor.ca/etd/6038 This online database contains the full-text of PhD dissertations and Masters’ theses of University of Windsor students from 1954 forward. These documents are made available for personal study and research purposes only, in accordance with the Canadian Copyright Act and the Creative Commons license—CC BY-NC-ND (Attribution, Non-Commercial, No Derivative Works). Under this license, works must always be attributed to the copyright holder (original author), cannot be used for any commercial purposes, and may not be altered. Any other use would require the permission of the copyright holder. Students may inquire about withdrawing their dissertation and/or thesis from this database. For additional inquiries, please contact the repository administrator via email ([email protected]) or by telephone at 519-253-3000ext. 3208. A STUDY OF THE DECOMPOSITION OF SOME AROMATIC DIAZONIUM HEXAFLUOROPHOSPHATE SALTS BY WILLIAM A. REDMOND A Thesis Submitted to the Faculty of Graduate Studies through' the Department of Chemistry in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy at the University of Windsor Windsor, Ontario 1964 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
    [Show full text]
  • Detection and Formation Scenario of Citric Acid, Pyruvic Acid, and Other Possible Metabolism Precursors in Carbonaceous Meteorites
    Detection and formation scenario of citric acid, pyruvic acid, and other possible metabolism precursors in carbonaceous meteorites George Coopera,1, Chris Reeda, Dang Nguyena, Malika Cartera, and Yi Wangb aExobiology Branch, Space Science Division, National Aeronautics and Space Administration-Ames Research Center, Moffett Field, CA 94035; and bDevelopment, Planning, Research, and Analysis/ZymaX Forensics Isotope, 600 South Andreasen Drive, Suite B, Escondido, CA 92029 Edited by David Deamer, University of California, Santa Cruz, CA, and accepted by the Editorial Board July 1, 2011 (received for review April 12, 2011) Carbonaceous meteorites deliver a variety of organic compounds chained three-carbon (3C) pyruvic acid through the eight-carbon to Earth that may have played a role in the origin and/or evolution (8C) 7-oxooctanoic acid and the branched 6C acid, 3-methyl- of biochemical pathways. Some apparently ancient and critical 4-oxopentanoic acid (β-methyl levulinic acid), Fig. 1, Table S1. metabolic processes require several compounds, some of which 2-methyl-4-oxopenanoic acid (α-methyl levulinic acid) is tenta- are relatively labile such as keto acids. Therefore, a prebiotic setting tively identified (i.e., identified by mass spectral interpretation for any such individual process would have required either a only). As a group, these keto acids are relatively unusual in that continuous distant source for the entire suite of intact precursor the ketone carbon is located in a terminal-acetyl group rather molecules and/or an energetic and compact local synthesis, parti- than at the second carbon as in most of the more biologically cularly of the more fragile members.
    [Show full text]
  • Bacterial Metabolism of Glycine and Alanine David Paretsky Iowa State College
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1948 Bacterial metabolism of glycine and alanine David Paretsky Iowa State College Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Biochemistry Commons, and the Microbiology Commons Recommended Citation Paretsky, David, "Bacterial metabolism of glycine and alanine " (1948). Retrospective Theses and Dissertations. 13762. https://lib.dr.iastate.edu/rtd/13762 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. NOTE TO USERS This reproduction is the best copy available. UMI BAG1ERIAL METABOLISM OP GL^CIKE AND ALANINE by David Paretsky A Itieais Submitted to the Graduate Faculty for the Degree of DOCTOR OP PHILOSOPHY Major Subjects physiological Bacteriology Approved? Signature was redacted for privacy. In Charge of Major Work Signature was redacted for privacy. Heaa'of' "la'jo'r 'Departn^en t Signature was redacted for privacy. Dean or Graduate -Golleg^ Iowa State College 1948 UMI Number: DP12896 INFORMATION TO USERS The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleed-through, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted.
    [Show full text]
  • NON-HAZARDOUS CHEMICALS May Be Disposed of Via Sanitary Sewer Or Solid Waste
    NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste (+)-A-TOCOPHEROL ACID SUCCINATE (+,-)-VERAPAMIL, HYDROCHLORIDE 1-AMINOANTHRAQUINONE 1-AMINO-1-CYCLOHEXANECARBOXYLIC ACID 1-BROMOOCTADECANE 1-CARBOXYNAPHTHALENE 1-DECENE 1-HYDROXYANTHRAQUINONE 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE HYDROCHLORIDE 1-NONENE 1-TETRADECENE 1-THIO-B-D-GLUCOSE 1-TRIDECENE 1-UNDECENE 2-ACETAMIDO-1-AZIDO-1,2-DIDEOXY-B-D-GLYCOPYRANOSE 2-ACETAMIDOACRYLIC ACID 2-AMINO-4-CHLOROBENZOTHIAZOLE 2-AMINO-2-(HYDROXY METHYL)-1,3-PROPONEDIOL 2-AMINOBENZOTHIAZOLE 2-AMINOIMIDAZOLE 2-AMINO-5-METHYLBENZENESULFONIC ACID 2-AMINOPURINE 2-ANILINOETHANOL 2-BUTENE-1,4-DIOL 2-CHLOROBENZYLALCOHOL 2-DEOXYCYTIDINE 5-MONOPHOSPHATE 2-DEOXY-D-GLUCOSE 2-DEOXY-D-RIBOSE 2'-DEOXYURIDINE 2'-DEOXYURIDINE 5'-MONOPHOSPHATE 2-HYDROETHYL ACETATE 2-HYDROXY-4-(METHYLTHIO)BUTYRIC ACID 2-METHYLFLUORENE 2-METHYL-2-THIOPSEUDOUREA SULFATE 2-MORPHOLINOETHANESULFONIC ACID 2-NAPHTHOIC ACID 2-OXYGLUTARIC ACID 2-PHENYLPROPIONIC ACID 2-PYRIDINEALDOXIME METHIODIDE 2-STEP CHEMISTRY STEP 1 PART D 2-STEP CHEMISTRY STEP 2 PART A 2-THIOLHISTIDINE 2-THIOPHENECARBOXYLIC ACID 2-THIOPHENECARBOXYLIC HYDRAZIDE 3-ACETYLINDOLE 3-AMINO-1,2,4-TRIAZINE 3-AMINO-L-TYROSINE DIHYDROCHLORIDE MONOHYDRATE 3-CARBETHOXY-2-PIPERIDONE 3-CHLOROCYCLOBUTANONE SOLUTION 3-CHLORO-2-NITROBENZOIC ACID 3-(DIETHYLAMINO)-7-[[P-(DIMETHYLAMINO)PHENYL]AZO]-5-PHENAZINIUM CHLORIDE 3-HYDROXYTROSINE 1 9/26/2005 NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste 3-HYDROXYTYRAMINE HYDROCHLORIDE 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE
    [Show full text]
  • APPENDIX G Acid Dissociation Constants
    harxxxxx_App-G.qxd 3/8/10 1:34 PM Page AP11 APPENDIX G Acid Dissociation Constants §␮ ϭ 0.1 M 0 ؍ (Ionic strength (␮ † ‡ † Name Structure* pKa Ka pKa ϫ Ϫ5 Acetic acid CH3CO2H 4.756 1.75 10 4.56 (ethanoic acid) N ϩ H3 ϫ Ϫ3 Alanine CHCH3 2.344 (CO2H) 4.53 10 2.33 ϫ Ϫ10 9.868 (NH3) 1.36 10 9.71 CO2H ϩ Ϫ5 Aminobenzene NH3 4.601 2.51 ϫ 10 4.64 (aniline) ϪO SNϩ Ϫ4 4-Aminobenzenesulfonic acid 3 H3 3.232 5.86 ϫ 10 3.01 (sulfanilic acid) ϩ NH3 ϫ Ϫ3 2-Aminobenzoic acid 2.08 (CO2H) 8.3 10 2.01 ϫ Ϫ5 (anthranilic acid) 4.96 (NH3) 1.10 10 4.78 CO2H ϩ 2-Aminoethanethiol HSCH2CH2NH3 —— 8.21 (SH) (2-mercaptoethylamine) —— 10.73 (NH3) ϩ ϫ Ϫ10 2-Aminoethanol HOCH2CH2NH3 9.498 3.18 10 9.52 (ethanolamine) O H ϫ Ϫ5 4.70 (NH3) (20°) 2.0 10 4.74 2-Aminophenol Ϫ 9.97 (OH) (20°) 1.05 ϫ 10 10 9.87 ϩ NH3 ϩ ϫ Ϫ10 Ammonia NH4 9.245 5.69 10 9.26 N ϩ H3 N ϩ H2 ϫ Ϫ2 1.823 (CO2H) 1.50 10 2.03 CHCH CH CH NHC ϫ Ϫ9 Arginine 2 2 2 8.991 (NH3) 1.02 10 9.00 NH —— (NH2) —— (12.1) CO2H 2 O Ϫ 2.24 5.8 ϫ 10 3 2.15 Ϫ Arsenic acid HO As OH 6.96 1.10 ϫ 10 7 6.65 Ϫ (hydrogen arsenate) (11.50) 3.2 ϫ 10 12 (11.18) OH ϫ Ϫ10 Arsenious acid As(OH)3 9.29 5.1 10 9.14 (hydrogen arsenite) N ϩ O H3 Asparagine CHCH2CNH2 —— —— 2.16 (CO2H) —— —— 8.73 (NH3) CO2H *Each acid is written in its protonated form.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin Et Al
    USOO91 01662B2 (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin et al. (45) Date of Patent: *Aug. 11, 2015 (54) COMPOSITIONS WITH MODULATING A61K 47/32 (2013.01); A61 K9/0014 (2013.01); AGENTS A61 K9/0031 (2013.01); A61 K9/0034 (2013.01); A61 K9/0043 (2013.01); A61 K (71) Applicant: Foamix Pharmaceuticals Ltd., Rehovot 9/0046 (2013.01); A61 K9/0048 (2013.01); (IL) A61 K9/0056 (2013.01) (72) Inventors: Dov Tamarkin, Macabim (IL); Meir (58) Field of Classification Search Eini, Ness Ziona (IL); Doron Friedman, CPC ........................................................ A61 K9/12 Karmei Yosef (IL); Tal Berman, Rishon See application file for complete search history. le Ziyyon (IL); David Schuz, Gimzu (IL) (56) References Cited (73) Assignee: Foamix Pharmaceuticals Ltd., Rehovot U.S. PATENT DOCUMENTS (IL) 1,159,250 A 11/1915 Moulton (*) Notice: Subject to any disclaimer, the term of this 1,666,684 A 4, 1928 Carstens patent is extended or adjusted under 35 1924,972 A 8, 1933 Beckert 2,085,733. A T. 1937 Bird U.S.C. 154(b) by 0 days. 2,390,921 A 12, 1945 Clark This patent is Subject to a terminal dis 2,524,590 A 10, 1950 Boe claimer. 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (21) Appl. No.: 14/045,528 2.968,628 A 1/1961 Reed 3,004,894 A 10/1961 Johnson et al. (22) Filed: Oct. 3, 2013 3,062,715 A 11/1962 Reese et al.
    [Show full text]
  • Safety Data Sheet
    SAFETY DATA SHEET Preparation Date: 07/06/2015 Revision Date: 12/28/2017 Revision Number: G2 1. IDENTIFICATION Product identifier Product code: C2322 Product Name: CYANOACETIC ACID Other means of identification Synonyms: Acide cyanacetique [French] Cyanessigsaeure [German] Kyselina kyanoctova [Czech] Malonic acid mononitrile Malonic mononitrile Monocyanoacetic acid Acetic acid, 2-cyano- Acetic acid, cyano- CAS #: 372-09-8 RTECS # AG3675000 CI#: Not available Recommended use of the chemical and restrictions on use Recommended use: Chemical intermediate for malonic acid; diethyl malonate for pharmaceuticals; For the production of the fungicide cymoxanil and the cough remedy dextromethorphan. Uses advised against No information available Supplier: Spectrum Chemical Mfg. Corp 14422 South San Pedro St. Gardena, CA 90248 (310) 516-8000 Order Online At: https://www.spectrumchemical.com Emergency telephone number Chemtrec 1-800-424-9300 Contact Person: Martin LaBenz (West Coast) Contact Person: Ibad Tirmiz (East Coast) 2. HAZARDS IDENTIFICATION Classification This chemical is considered hazardous according to the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200) Considered a dangerous substance or mixture according to the Globally Harmonized System (GHS) Acute toxicity - Oral Category 4 Skin corrosion/irritation Category 1 Serious eye damage/eye irritation Category 1 Specific target organ toxicity (single exposure) Category 3 Label elements Product code: C2322 Product name: CYANOACETIC ACID 1 / 12 Danger Hazard statements Causes severe
    [Show full text]
  • Microflex Gloves Chemical Compatibility Chart
    1 1 1 2 2 3 1 CAUTION (LATEX): This product contains natural rubber 2 CAUTION (NITRILE: MEDICAL GRADE): Components used 3 CAUTION (NITRILE: NON-MEDICAL GRADE)): These latex (latex) which may cause allergic reactions. Safe use in making these gloves may cause allergic reactions in gloves are for non-medical use only. They may NOT be of this glove by or on latex sensitized individuals has not some users. Follow your institution’s policies for use. worn for barrier protection in medical or healthcare been established. applications. Please select other gloves for these applications. Components used in making these gloves may cause allergic reactions in some users. Follow your institution’s policies for use. For single use only. NeoPro® Chemicals NeoPro®EC Ethanol ■NBT Ethanolamine (99%) ■NBT Ether ■2 Ethidium bromide (1%) ■NBT Ethyl acetate ■1 Formaldehyde (37%) ■NBT Formamide ■NBT Gluteraldehyde (50%) ■NBT Test Method Description: The test method uses analytical Guanidine hydrochloride ■NBT equipment to determine the concentration of and the time at which (50% ■0 the challenge chemical permeates through the glove film. The Hydrochloric acid ) liquid challenge chemical is collected in a liquid miscible chemical Isopropanol ■NBT (collection media). Data is collected in three separate cells; each cell Methanol ■NBT is compared to a blank cell which uses the same collection media as both the challenge and Methyl ethyl ketone ■0 collection chemical. Methyl methacrylate (33%) ■0 Cautionary Information: These glove recommendations are offered as a guide and for reference Nitric acid (50%) ■NBT purposes only. The barrier properties of each glove type may be affected by differences in material Periodic acid (50%) ■NBT thickness, chemical concentration, temperature, and length of exposure to chemicals.
    [Show full text]